Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07192341
NA

Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction

Sponsor: Kafrelsheikh University

View on ClinicalTrials.gov

Summary

This study aims to evaluate the effect of sacubitril/valsartan in patients with prosthetic heart valves with heart failure with reduced ejection fraction (HFrEF).

Official title: Effect of Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

220

Start Date

2025-09-27

Completion Date

2026-02-01

Last Updated

2025-09-30

Healthy Volunteers

No

Interventions

DRUG

Sacubitril/Valsartan

Patients will be treated with conventional anti-heart failure therapy plus sacubitril/valsartan (oral administration of an initial dose of 24/26 mg twice daily, gradually increasing to 97/103 mg, depending on follow-up blood pressure) \[Entresto, 100 mg (sacubitril 49 mg/valsartan 51 mg)\].

DRUG

Conventional anti-heart failure therapy

Patients will be treated only with conventional anti-heart failure therapy as a control group.

Locations (1)

Kafrelsheikh University

Kafr ash Shaykh, Kafrelsheikh, Egypt